Cytek Biosciences Inc (CTKB)

Return on total capital

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands -20,524 -15,467 -19,331 -18,465 -18,280 -13,342 -7,253 -1,821 3,833 579 596 5,050 8,290 14,619 19,002 15,495 14,307
Long-term debt US$ in thousands — — — — — — — — — — — — — — — — —
Total stockholders’ equity US$ in thousands 395,737 385,463 389,123 392,614 393,064 415,524 424,179 423,460 425,295 416,447 411,027 407,236 406,458 403,055 -11,300 -15,072 -16,028
Return on total capital -5.19% -4.01% -4.97% -4.70% -4.65% -3.21% -1.71% -0.43% 0.90% 0.14% 0.15% 1.24% 2.04% 3.63% — — —

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-20,524K ÷ ($—K + $395,737K)
= -5.19%

Return on total capital measures the efficiency of a company in generating profits from its total capital employed. From December 2020 to December 2024, Cytek Biosciences Inc experienced a declining trend in its return on total capital. The ratio declined from 3.63% in September 2021 to -5.19% by the end of December 2024.

The negative values indicate that the company's capital was not effectively utilized to generate profits during these periods. This downward trend may signal potential issues with the company's operational efficiency or profitability. It is important for Cytek Biosciences Inc to closely monitor and address the factors contributing to the decreasing return on total capital to ensure sustainable profitability and positive performance in the future.